Eli Lilly becomes the first drugmaker to get approval for a GLP-1 weight loss pill in China
Eli Lilly has received approval in China for its weight-loss pill, orforglipron, making it the first pharmaceutical company to obtain approval for an oral GLP-1 medicine for weight management in the country. This gives the company an early advantage over its competitor, Novo Nordisk, whose oral weight-loss pill is still awaiting approval in China.
Eli Lilly announced the approval on November 12, 2026. It was granted by China’s National Medical Products Administration (NMPA), the country’s drug regulator. This is a marketing approval, which means orforglipron can be sold in China once Eli Lilly completes its launch. The company had submitted its application to the NMPA at the end of 2025, and the regulator accepted it for review in January 2026. Their medicine, known as Fondio in the United States, is taken as a once-daily pill.
Until now, GLP-1 medicines approved for weight loss in China have been available only as injections. With this approval, patients will have another option that does not require an injection.
Below, we look at what makes this medicine different and why pharmaceutical companies are investing so heavily in GLP-1 drugs.
What is special about Eli Lilly’s new weight loss pill?
Orforglipron belongs to a group of medicines called GLP-1 receptor agonists.
GLP-1 (Glucagon-Like Peptide-1) is a hormone that is naturally produced in our body that helps regulate appetite and blood sugar levels.
GLP-1 receptor agonists mimic the action of this hormone. They increase the feeling of fullness from meals, reduce appetite, and slow gastric emptying (the rate at which food leaves the stomach). Together, these effects reduce food intake, leading to weight loss.
Most GLP-1 medicines currently approved for weight management are given as injections, whereas orforglipron is a small-molecule drug taken once daily orally. An oral option may suit patients who do not prefer to use injections.
What did the clinical trials show?
Before receiving approval, orforglipron was evaluated in clinical trials to assess its efficacy and safety.
In the Phase 3 ATTAIN 1 clinical trial, Eli Lilly studied the medicine in 3,127 adults with obesity or overweight who did not have diabetes.
The results showed that participants who received the highest dose (36mg) of orforglipron lost an average of 11.2% of their body weight after 72 weeks. Among those who stayed on treatment as planned, the average weight loss was 12.4%.
In comparison, participants who received a placebo lost around 2.1% of their body weight ( A Placebo is a dummy treatment with no active medicine; it helps the researchers understand whether the actual medicine is responsible for the observed results)
The trial showed that orforglipron produced significantly greater weight loss than placebo
Note: these results are from a clinical trial, and the amount of weight loss may vary from person to person.
Eli Lilly vs Novo Nordisk: competition in the weight loss drug market
Eli Lilly is not the only pharmaceutical company which is working on oral medicines for weight management. Its major competitor, Novo Nordisk, is also trying to strengthen its position in the market.
Novo Nordisk has its own oral GLP-1 weight loss medicine, an oral version of its popular drug Wegovy. Its active ingredient is semaglutide, which also belongs to the GLP-1 class. The oral Wegovy is already approved and sold in the United States, but in China it is still under regulatory review. China’s drug regulator accepted Novo Nordisk’s application in August 2026, and the medicine has not been approved yet as of November 12, 2026.
The two medicines have shown different weight-loss results in their respective main clinical trials. Novo Nordisk’s oral Wegovy achieved an average weight reduction of 13.6% over 64 weeks in the OASIS 4 trial, while Eli Lilly’s orforglipron achieved an average weight reduction of 11.2% over 72 weeks in the ATTAIN-1 trial.
Note: These results come from separate clinical trials; therefore, they cannot be used to directly decide which medicine is better.
According to data shared by Novo Nordisk in September 2026, oral medicines already account for around one-third of obesity prescriptions. In the United States, the company also reported that it holds more than 80% of the new prescription volume for oral obesity medicines.
With both companies competing in this market, the coming years could bring further developments in oral weight-loss treatments.
China’s weight-loss medicine market is expected to grow
China has one of the world’s largest populations living with overweight and obesity, which makes it a key market for obesity medicines. According to China’s National Health Commission (NHC), more than half of Chinese adults were overweight or obese in 2020 (34.3% overweight and 16.4% obese). The NHC projects that this share could rise to 65.3% by 2030 if current trends continue. This growing burden is driving demand for effective weight management treatments.
According to a forecast by Yang Huang, J.P. Morgan’s head of China healthcare research, annual sales of GLP-1 medicines for weight management in China could reach 30 billion yuan (approximately US$4.5 billion) over the next 5 to 7 years.
At present, the market is estimated to generate between 3 and 4 billion yuan annually.
However, pharmaceutical companies may also face challenges. The expected launch of generic semaglutide medicines and restrictions on online medicine sales could increase competition and put pressure on drug prices.
What is Eli Lilly planning next?
Following the approval, Eli Lilly said it is working towards launching orforglipron in China.
The company also stated that it would supply the medicine through authorised healthcare and pharmaceutical institutions. The company has not yet announced the price of the medicine in China.
Several Chinese drug makers, including Jiuangshou, Hengrui Pharmaceuticals, and Huadong Medicine, are also developing oral GLP-1 medicines.
As more companies enter this market, competition is expected to increase, giving patients more treatment options in the future.
Getting a medicine approved involves regulatory submissions, documentation, and compliance with national requirements. Students interested in this field can explore Global Regulatory Affairs training with project work
What does this mean for the pharmaceutical industry?
Eli Lilly’s latest approval shows how pharmaceutical companies are working to develop medicines that are not only effective but also easier for patients to take.
For many years, injectable GLP-1 medications have been an important part of obesity treatment. The development of oral alternatives is now creating another direction for research and drug development.
This also highlights the importance of clinical research, drug discovery, regulatory approvals, and pharmaceutical manufacturing in bringing new medicines to patients.
With Eli Lilly receiving the first approval in China for an oral GLP-1 weight-loss medicine, competition in the global obesity treatment market is expected to intensify in the coming years.
For pharmacy graduates interested in the industry, these developments highlight opportunities in clinical research, drug development and regulatory affairs. Explore our B.Pharm career guide to understand different pharmaceutical career paths.